Literature DB >> 17638582

Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect.

T V Gerdjikov1, U Rudolph, R Keist, H Möhler, J Feldon, B K Yee.   

Abstract

Hippocampal GABA(A) receptors containing the alpha 5 subunit have been implicated in the modulation of hippocampal-dependent learning, presumably via their tonic inhibitory influence on hippocampal glutamatergic activity. Here, we examined the expression of latent inhibition (LI)--a form of selective learning that is sensitive to a number of manipulations targeted at the hippocampal formation, in alpha 5(H105R) mutant mice with reduced levels of hippocampal alpha 5-containing GABA(A) receptors. A single pre-exposure to the taste conditioned stimulus (CS) prior to the pairing of the same CS with LiCl-induced nausea was effective in reducing the conditioned aversion against the taste CS in wild-type mice--thus constituting the LI effect. LI was however distinctly absent in male alpha 5(H105R) mutant mice. Hence, a partial loss of hippocampal alpha 5 GABA(A) receptors is sufficient to alter one major form of selective learning, albeit this was not seen in the female. This observed phenotype suggests that specific activation of these extrasynaptic GABA(A) receptors may confer therapeutic potential against the failure to show selectivity in learning by human psychotic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638582     DOI: 10.1016/j.nlm.2007.06.003

Source DB:  PubMed          Journal:  Neurobiol Learn Mem        ISSN: 1074-7427            Impact factor:   2.877


  21 in total

Review 1.  GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.

Authors:  S Hossein Fatemi; Timothy D Folsom
Journal:  Schizophr Res       Date:  2014-11-26       Impact factor: 4.939

2.  A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.

Authors:  Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2011-05-11       Impact factor: 7.853

3.  Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.

Authors:  John P Redrobe; Lisbeth Elster; Kristen Frederiksen; Christoffer Bundgaard; Inge E M de Jong; Garrick P Smith; Anne Techau Bruun; Peter H Larsen; Michael Didriksen
Journal:  Psychopharmacology (Berl)       Date:  2011-11-29       Impact factor: 4.530

Review 4.  GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia.

Authors:  Meng-Yi Xu; Albert H C Wong
Journal:  Acta Pharmacol Sin       Date:  2018-03-22       Impact factor: 6.150

5.  GABAA receptor alpha5 subunits contribute to GABAA,slow synaptic inhibition in mouse hippocampus.

Authors:  Ewa D Zarnowska; Ruth Keist; Uwe Rudolph; Robert A Pearce
Journal:  J Neurophysiol       Date:  2008-12-10       Impact factor: 2.714

Review 6.  An Emerging Circuit Pharmacology of GABAA Receptors.

Authors:  Elif Engin; Rebecca S Benham; Uwe Rudolph
Journal:  Trends Pharmacol Sci       Date:  2018-06-11       Impact factor: 14.819

7.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

8.  Contribution of GABAA receptor subunits to attention and social behavior.

Authors:  Tracie A Paine; Sara Chang; Rachel Poyle
Journal:  Behav Brain Res       Date:  2019-09-24       Impact factor: 3.332

9.  Prepulse inhibition and genetic mouse models of schizophrenia.

Authors:  Susan B Powell; Xianjin Zhou; Mark A Geyer
Journal:  Behav Brain Res       Date:  2009-05-04       Impact factor: 3.332

Review 10.  The role of α5 GABAA receptor agonists in the treatment of cognitive deficits in schizophrenia.

Authors:  Kathryn M Gill; Anthony A Grace
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.